Etohi1 inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the function of the Etohi1 protein, which is involved in a range of cellular processes. Etohi1 is a member of a larger family of enzymes known for their role in regulating various intracellular activities, including the modulation of signaling pathways and protein interactions. Inhibitors of Etohi1 function by binding to the active site or an allosteric site on the protein, thereby obstructing its normal function. This binding is often achieved through the formation of a non-covalent or covalent complex, which effectively reduces or abolishes the enzyme's activity. The development of Etohi1 inhibitors typically involves a combination of high-throughput screening, computational modeling, and structure-based drug design to identify and optimize molecules with high specificity and affinity for the target enzyme.
The structural diversity of Etohi1 inhibitors reflects the complexity of the enzyme's active site and the need for precise molecular interactions to achieve effective inhibition. These inhibitors often contain a variety of functional groups that can engage in multiple types of interactions with the protein, such as hydrogen bonding, van der Waals forces, and hydrophobic interactions. Additionally, the design of these inhibitors takes into consideration the enzyme's conformational flexibility, which can influence how inhibitors bind and modulate enzyme activity. Advanced techniques like X-ray crystallography, NMR spectroscopy, and molecular docking are frequently employed to study the binding interactions at an atomic level, providing insights that guide the refinement of inhibitor design. The goal in developing Etohi1 inhibitors is to create compounds that are not only potent but also selective for Etohi1, reducing the likelihood of cross-reactivity with other proteins in the same family. This specificity is crucial for understanding the precise role of Etohi1 in cellular processes and for studying its biochemical pathways in detail.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol activates Etohi1 by modulating SIRT1 activity. It enhances the deacetylation function of SIRT1, promoting Etohi1 activation and influencing downstream cellular processes. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin activates Etohi1 by inhibiting phosphoinositide 3-kinase (PI3K) and downstream Akt signaling. Its impact on the PI3K/Akt pathway can lead to Etohi1 activation and modulation of cellular processes associated with Etohi1. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine activates Etohi1 by promoting AMP-activated protein kinase (AMPK) activation. Activation of AMPK by berberine can potentially influence Etohi1 and its downstream cellular processes. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin activates Etohi1 by inhibiting the NF-κB pathway. Its suppression of NF-κB signaling may lead to Etohi1 activation and modulation of cellular processes associated with Etohi1. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin activates Etohi1 by promoting AMPK activation. Its impact on AMPK can potentially influence Etohi1 and its downstream cellular processes. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG activates Etohi1 by modulating SIRT1 activity. It enhances the deacetylation function of SIRT1, promoting Etohi1 activation and influencing downstream cellular processes. | ||||||
Diosmin | 520-27-4 | sc-204728 sc-204728A | 5 g 25 g | $58.00 $114.00 | 2 | |
Diosmin activates Etohi1 by inhibiting the PI3K/Akt pathway. Its impact on PI3K/Akt signaling may lead to Etohi1 activation and modulation of cellular processes associated with Etohi1. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $27.00 $51.00 $101.00 $153.00 $1925.00 | 40 | |
Luteolin activates Etohi1 by inhibiting the NF-κB pathway. Its suppression of NF-κB signaling may lead to Etohi1 activation and modulation of cellular processes associated with Etohi1. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates Etohi1 by promoting AMPK activation. Its influence on AMPK can potentially impact Etohi1 and its downstream cellular processes. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
Sulforaphane activates Etohi1 by enhancing Nrf2 activity. It induces Nrf2-mediated antioxidant responses, promoting Etohi1 activation and influencing cellular processes associated with Etohi1. | ||||||